A Study of Second-line Treatment With Apatinib for Advanced Intrahepatic Cholangiocarcinoma
The propose of this study is to confirm safety and efficacy of Apatinib monotherapy in patients with advanced cholangiocarcinoma.
Intrahepatic Cholangiocarcinoma
DRUG: Apatinib
Disease Control Rate (DCR), the percentage of patients with advanced or metastatic cancer who have achieved complete response, partial response and stable disease, 1 month
Progression-free Survival, Time from start of treatment until the first documented event of symptomatic progression or death., 24 month|Objective Response Rate(ORR), Proportion of patients with reduction in tumor burden of a predefined amount, 1 month, 3 month, 6 month|Overall Survival, from start of treatment to death from any cause, or last known date of survival, 36 month
The propose of this study is to confirm safety and efficacy of Apatinib monotherapy in patients with advanced cholangiocarcinoma.